Torrent Pharmaceuticals Ltd on Friday reported a strong set of earnings for the quarter ended September 2025 (Q2 FY26), posting a 30.4% year-on-year increase in net profit to ₹591 crore, compared with ₹453 crore in the same period last year.

Revenue from operations rose 14.3% to ₹3,302 crore from ₹2,889 crore a year earlier, while EBITDA grew 15.3% to ₹1,083 crore, maintaining a healthy operating margin of 32.8%, slightly higher than 32.5% in the corresponding quarter of the previous year.

The company’s India business, its largest contributor, delivered a healthy 12% growth to ₹1,820 crore, led by continued outperformance in focus therapies and strong momentum in the chronic portfolio, which grew 13% versus IPM growth of 11%.

Also Read : AstraZeneca Pharma Q2 Results: Profit jumps 4

See Full Page